111 related articles for article (PubMed ID: 18680162)
1. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative.
Colavolpe C; Guedj E; Cammilleri S; Taïeb D; Mundler O; Coze C
Pediatr Blood Cancer; 2008 Dec; 51(6):828-31. PubMed ID: 18680162
[TBL] [Abstract][Full Text] [Related]
2. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative.
Mc Dowell H; Losty P; Barnes N; Kokai G
Pediatr Blood Cancer; 2009 Apr; 52(4):552. PubMed ID: 19058210
[No Abstract] [Full Text] [Related]
3. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
4. Disparities in uptake pattern of (123)I-MIBG, (18)F-FDG, and (99m)Tc-MDP within the same primary neuroblastoma.
Codreanu I; Zhuang H
Clin Nucl Med; 2014 Feb; 39(2):e184-6. PubMed ID: 23676656
[TBL] [Abstract][Full Text] [Related]
5. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Guay C; Lépine M; Verreault J; Bénard F
J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
[TBL] [Abstract][Full Text] [Related]
7. ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma.
Melzer HI; Coppenrath E; Schmid I; Albert MH; von Schweinitz D; Tudball C; Bartenstein P; Pfluger T
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1648-58. PubMed ID: 21617976
[TBL] [Abstract][Full Text] [Related]
8. [Neuroblastoma staging: discrepancies between ¹⁸F-FDG-PET and ¹²³I-MIBG].
Mena LM; Muros MA; Palacios H; Moreno MJ; Santiago A; Llamas JM
An Pediatr (Barc); 2010 Dec; 73(6):363-4. PubMed ID: 20817583
[No Abstract] [Full Text] [Related]
9. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
Sharp SE; Shulkin BL; Gelfand MJ; Salisbury S; Furman WL
J Nucl Med; 2009 Aug; 50(8):1237-43. PubMed ID: 19617326
[TBL] [Abstract][Full Text] [Related]
10. [123I]MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging.
Rufini V; Giordano A; Di Giuda D; Petrone A; Deb G; De Sio L; Donfrancesco A; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):25-8. PubMed ID: 9002745
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography for Follow-Up of 13-cis-Retinoic Acid Treatment for Residual Neuroblastoma After Myeloablative Chemotherapy.
Sato Y; Kurosawa H; Sakamoto S; Kuwashima S; Hashimoto T; Okamoto K; Tsuchioka T; Fukushima K; Arisaka O
Medicine (Baltimore); 2015 Aug; 94(31):e1290. PubMed ID: 26252303
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.
Shulkin BL; Hutchinson RJ; Castle VP; Yanik GA; Shapiro B; Sisson JC
Radiology; 1996 Jun; 199(3):743-50. PubMed ID: 8637999
[TBL] [Abstract][Full Text] [Related]
13. PET/CT imaging in neuroblastoma.
Piccardo A; Lopci E; Conte M; Foppiani L; Garaventa A; Cabria M; Villavecchia G; Fanti S; Cistaro A
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):29-39. PubMed ID: 23474633
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
Schmidt M; Simon T; Hero B; Schicha H; Berthold F
Eur J Cancer; 2008 Jul; 44(11):1552-8. PubMed ID: 18424129
[TBL] [Abstract][Full Text] [Related]
15. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.
Taggart DR; Han MM; Quach A; Groshen S; Ye W; Villablanca JG; Jackson HA; Mari Aparici C; Carlson D; Maris J; Hawkins R; Matthay KK
J Clin Oncol; 2009 Nov; 27(32):5343-9. PubMed ID: 19805691
[TBL] [Abstract][Full Text] [Related]
16. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
Nguyen NC; Bhatla D; Osman MM
J Nucl Med; 2010 Feb; 51(2):330-1; author reply 331. PubMed ID: 20080890
[No Abstract] [Full Text] [Related]
17. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
18. Abnormal FDG and MIBG Activity in the Bones in a Patient With Neuroblastoma Without Detectable Primary Tumor.
Zhang W; Zhuang H; Servaes S
Clin Nucl Med; 2016 Aug; 41(8):632-3. PubMed ID: 26825196
[TBL] [Abstract][Full Text] [Related]
19. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.
Cistaro A; Quartuccio N; Caobelli F; Piccardo A; Paratore R; Coppolino P; Sperandeo A; Arnone G; Ficola U
Nucl Med Rev Cent East Eur; 2015; 18(2):102-6. PubMed ID: 26315872
[TBL] [Abstract][Full Text] [Related]
20. Benign differentiation of treated neuroblastoma as a cause of false positive by
Garcia JR; Bassa P; Soler M; Jaramillo A; Ortiz S; Riera E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(6):389-390. PubMed ID: 31000447
[No Abstract] [Full Text] [Related]
[Next] [New Search]
